Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients

Risankizumab has demonstrated efficacy in phase III trials in patients with moderate‐to‐severe plaque psoriasis. The exposure–response relationships for risankizumab efficacy (Psoriasis Area and Severity Index (PASI)75, PASI90, PASI100, and static Physician's Global Assessment (sPGA)0/1) at wee...

Descripción completa

Detalles Bibliográficos
Autores principales: Khatri, Amit, Suleiman, Ahmed A., Polepally, Akshanth R., Othman, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006881/
https://www.ncbi.nlm.nih.gov/pubmed/31355921
http://dx.doi.org/10.1002/cpt.1594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006881/
https://www.ncbi.nlm.nih.gov/pubmed/31355921
http://dx.doi.org/10.1002/cpt.1594

Ejemplares similares